IndraLab

Statements


QA L inhibits KCNK2. 1 / 1
| 1

reach
"Furthermore, TREK-1 activation with 2-APB or ML335 was not antagonized by QA L + inhibition and mutations at the BL-1249 site did not affect 2-APB activation (XREF_SUPPLEMENTARY)."